Neuroradiological interventions in cerebrovascular disease: Intracranial revascularization

Martin Radvany, Philippe Gailloud

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Intracranial atherosclerotic disease (ICAD), the most common cause of stroke worldwide (1), is characterized by progressive involvement of the major intracranial arteries and is associated with a high risk of new and recurrent strokes (2). In particular, patients with a history of recent transient ischemic attack or stroke and a significant intracranial stenosis (70-99%) have been shown to be prone to recurrent stroke despite treatment with aspirin and management of their vascular risk factors (3). The use of percutaneous angioplasty, with and without stent placement, has been proposed in this patient population as an effort to decrease the incidence of new ischemic events and improve outcomes. Angioplasty alone has a technical success rate of over 80% (4-7). When performed on an elective basis, complication rates as low as 4-6% have been observed (4,8), leading some practitioners to advocate the use of angioplasty only. However, angioplasty followed by stent placement is usually preferred, as it overcomes some of the limitations of angioplasty alone, including immediate elastic recoil, dissection, acute vessel closure, and residual stenosis. Both balloon-expandable and self-expanding stents have been used, with a technical success rate exceeding 90% (9-13). The Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial (13) was the first randomized, prospective trial to compare endovascular treatment with the Wingspan stent system (Boston Scientific, Natick, MA) with best medical management. Enrollment in the trial was stopped after 451 patients because of a stroke or death rate of 14.7% in the stenting group versus 5.8% in the medical management group. The surprising findings in this study were that the risk of stroke with medical management was lower than expected, while the risk of PTAS with the Wingspan system was higher than expected. The principal message of the SAMMPRIS study is that intracranial stenting cannot be considered as the first line therapy of ICAD at this time. However, two important points must be remembered: 1) the SAMMPRIS study investigated a single device (the Wingspan system), and 2) intracranial stenting remains an important tool for patients with ICAD failing optimal medical therapy.

Original languageEnglish (US)
Title of host publicationCritical Care of the Stroke Patient
PublisherCambridge University Press
Pages120-128
Number of pages9
ISBN (Print)9780511659096, 9780521762564
DOIs
StatePublished - Jan 1 2013

Fingerprint

Cerebrovascular Disorders
Angioplasty
Stroke
Stents
Pathologic Constriction
Therapeutics
Transient Ischemic Attack
Aspirin
Dissection
Arteries
Equipment and Supplies
Mortality
Incidence
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Radvany, M., & Gailloud, P. (2013). Neuroradiological interventions in cerebrovascular disease: Intracranial revascularization. In Critical Care of the Stroke Patient (pp. 120-128). Cambridge University Press. https://doi.org/10.1017/CBO9780511659096.012

Neuroradiological interventions in cerebrovascular disease : Intracranial revascularization. / Radvany, Martin; Gailloud, Philippe.

Critical Care of the Stroke Patient. Cambridge University Press, 2013. p. 120-128.

Research output: Chapter in Book/Report/Conference proceedingChapter

Radvany, M & Gailloud, P 2013, Neuroradiological interventions in cerebrovascular disease: Intracranial revascularization. in Critical Care of the Stroke Patient. Cambridge University Press, pp. 120-128. https://doi.org/10.1017/CBO9780511659096.012
Radvany M, Gailloud P. Neuroradiological interventions in cerebrovascular disease: Intracranial revascularization. In Critical Care of the Stroke Patient. Cambridge University Press. 2013. p. 120-128 https://doi.org/10.1017/CBO9780511659096.012
Radvany, Martin ; Gailloud, Philippe. / Neuroradiological interventions in cerebrovascular disease : Intracranial revascularization. Critical Care of the Stroke Patient. Cambridge University Press, 2013. pp. 120-128
@inbook{b7b39b6d945e42c99d25aecd293428a1,
title = "Neuroradiological interventions in cerebrovascular disease: Intracranial revascularization",
abstract = "Introduction Intracranial atherosclerotic disease (ICAD), the most common cause of stroke worldwide (1), is characterized by progressive involvement of the major intracranial arteries and is associated with a high risk of new and recurrent strokes (2). In particular, patients with a history of recent transient ischemic attack or stroke and a significant intracranial stenosis (70-99{\%}) have been shown to be prone to recurrent stroke despite treatment with aspirin and management of their vascular risk factors (3). The use of percutaneous angioplasty, with and without stent placement, has been proposed in this patient population as an effort to decrease the incidence of new ischemic events and improve outcomes. Angioplasty alone has a technical success rate of over 80{\%} (4-7). When performed on an elective basis, complication rates as low as 4-6{\%} have been observed (4,8), leading some practitioners to advocate the use of angioplasty only. However, angioplasty followed by stent placement is usually preferred, as it overcomes some of the limitations of angioplasty alone, including immediate elastic recoil, dissection, acute vessel closure, and residual stenosis. Both balloon-expandable and self-expanding stents have been used, with a technical success rate exceeding 90{\%} (9-13). The Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial (13) was the first randomized, prospective trial to compare endovascular treatment with the Wingspan stent system (Boston Scientific, Natick, MA) with best medical management. Enrollment in the trial was stopped after 451 patients because of a stroke or death rate of 14.7{\%} in the stenting group versus 5.8{\%} in the medical management group. The surprising findings in this study were that the risk of stroke with medical management was lower than expected, while the risk of PTAS with the Wingspan system was higher than expected. The principal message of the SAMMPRIS study is that intracranial stenting cannot be considered as the first line therapy of ICAD at this time. However, two important points must be remembered: 1) the SAMMPRIS study investigated a single device (the Wingspan system), and 2) intracranial stenting remains an important tool for patients with ICAD failing optimal medical therapy.",
author = "Martin Radvany and Philippe Gailloud",
year = "2013",
month = "1",
day = "1",
doi = "10.1017/CBO9780511659096.012",
language = "English (US)",
isbn = "9780511659096",
pages = "120--128",
booktitle = "Critical Care of the Stroke Patient",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Neuroradiological interventions in cerebrovascular disease

T2 - Intracranial revascularization

AU - Radvany, Martin

AU - Gailloud, Philippe

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Introduction Intracranial atherosclerotic disease (ICAD), the most common cause of stroke worldwide (1), is characterized by progressive involvement of the major intracranial arteries and is associated with a high risk of new and recurrent strokes (2). In particular, patients with a history of recent transient ischemic attack or stroke and a significant intracranial stenosis (70-99%) have been shown to be prone to recurrent stroke despite treatment with aspirin and management of their vascular risk factors (3). The use of percutaneous angioplasty, with and without stent placement, has been proposed in this patient population as an effort to decrease the incidence of new ischemic events and improve outcomes. Angioplasty alone has a technical success rate of over 80% (4-7). When performed on an elective basis, complication rates as low as 4-6% have been observed (4,8), leading some practitioners to advocate the use of angioplasty only. However, angioplasty followed by stent placement is usually preferred, as it overcomes some of the limitations of angioplasty alone, including immediate elastic recoil, dissection, acute vessel closure, and residual stenosis. Both balloon-expandable and self-expanding stents have been used, with a technical success rate exceeding 90% (9-13). The Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial (13) was the first randomized, prospective trial to compare endovascular treatment with the Wingspan stent system (Boston Scientific, Natick, MA) with best medical management. Enrollment in the trial was stopped after 451 patients because of a stroke or death rate of 14.7% in the stenting group versus 5.8% in the medical management group. The surprising findings in this study were that the risk of stroke with medical management was lower than expected, while the risk of PTAS with the Wingspan system was higher than expected. The principal message of the SAMMPRIS study is that intracranial stenting cannot be considered as the first line therapy of ICAD at this time. However, two important points must be remembered: 1) the SAMMPRIS study investigated a single device (the Wingspan system), and 2) intracranial stenting remains an important tool for patients with ICAD failing optimal medical therapy.

AB - Introduction Intracranial atherosclerotic disease (ICAD), the most common cause of stroke worldwide (1), is characterized by progressive involvement of the major intracranial arteries and is associated with a high risk of new and recurrent strokes (2). In particular, patients with a history of recent transient ischemic attack or stroke and a significant intracranial stenosis (70-99%) have been shown to be prone to recurrent stroke despite treatment with aspirin and management of their vascular risk factors (3). The use of percutaneous angioplasty, with and without stent placement, has been proposed in this patient population as an effort to decrease the incidence of new ischemic events and improve outcomes. Angioplasty alone has a technical success rate of over 80% (4-7). When performed on an elective basis, complication rates as low as 4-6% have been observed (4,8), leading some practitioners to advocate the use of angioplasty only. However, angioplasty followed by stent placement is usually preferred, as it overcomes some of the limitations of angioplasty alone, including immediate elastic recoil, dissection, acute vessel closure, and residual stenosis. Both balloon-expandable and self-expanding stents have been used, with a technical success rate exceeding 90% (9-13). The Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial (13) was the first randomized, prospective trial to compare endovascular treatment with the Wingspan stent system (Boston Scientific, Natick, MA) with best medical management. Enrollment in the trial was stopped after 451 patients because of a stroke or death rate of 14.7% in the stenting group versus 5.8% in the medical management group. The surprising findings in this study were that the risk of stroke with medical management was lower than expected, while the risk of PTAS with the Wingspan system was higher than expected. The principal message of the SAMMPRIS study is that intracranial stenting cannot be considered as the first line therapy of ICAD at this time. However, two important points must be remembered: 1) the SAMMPRIS study investigated a single device (the Wingspan system), and 2) intracranial stenting remains an important tool for patients with ICAD failing optimal medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=84928594155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928594155&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511659096.012

DO - 10.1017/CBO9780511659096.012

M3 - Chapter

AN - SCOPUS:84928594155

SN - 9780511659096

SN - 9780521762564

SP - 120

EP - 128

BT - Critical Care of the Stroke Patient

PB - Cambridge University Press

ER -